Continuous Glucose Monitoring (CGM) Product Intelligence

Performance of Individual CGM Products & Brands

The commercial evolution of continuous glucose monitoring across Dexcom and Abbott products, along with others have been centrally analyzed. Our product-level intelligence combines annual estimated revenue, sensor volumes, manufacturer average selling prices (ASP), patient base and consumption patterns with analysis of device launches, wear-duration changes, market access and competitive substitution.

Six featured product coverages below and choose a focused, multi-product or cross-brand package aligned with your commercial decisions.

Six featured product coverages

Key questions answered in this analysis

• Which CGM products are generating revenue, and how might their product-level sales projections change through 2033?

• How do longer sensor-wear durations affect annual unit consumption and manufacturer revenue per CGM sensor?

• Where are established CGM devices losing demand to successor products?

• How do prescription CGM products compare with emerging OTC and dual-analyte offerings?

• What shifts in product adoption, pricing, reimbursement, distribution and regulatory status could change competitive positioning of CGMs?

What the deliverable contains

Temporal treatment: Historical estimates start when a product is commercially available; unlaunched products such as G8 are forecast-only. The 2022–2033 headline denotes the overall dataset window, not a claim of observed sales for every product in every year.

CGM Products : Currently Available & To be Launched

From G6 to G7 15 Day: Transition economics

The Dexcom G6 is an earlier-generation continuous glucose monitoring (CGM) system from Dexcom. In March 2018, it became the first CGM authorized by the FDA, cleared through the De Novo pathway as an integrated CGM system that allows interoperability with compatible diabetes devices and removes the need for routine fingerstick calibration. The system includes a 10-day sensor, glucose readings every five minutes, predictive alerts, and smartphone connectivity. Dexcom announced Medicare coverage for eligible beneficiaries in October 2018, helping to broaden access to technology. In February 2019, the FDA cleared the G6 as a factory-calibrated CGM system through the 510(k) pathway, reinforcing its role in diabetes management.

Dexcom G7 Continuous Glucose Monitoring (CGM) Revenue & Volume Analysis: A Deep Dive Into Dexcom G7, 2022–2033

Dexcom, Inc. is a U.S.-based medical device company that specializes in continuous glucose monitoring (CGM) systems; it was founded in 1999 and is headquartered in San Diego, California. Its portfolio comprises the Dexcom G7, G7 15 Day, G6, and Stelo, an over-the-counter glucose biosensor intended for eligible adults. These products deliver real-time glucose readings, customizable alerts, and connectivity with compatible digital health platforms.

The Dexcom G7 gained FDA clearance in December 2022 and was launched in the U.S. in 2023, offering an integrated sensor-transmitter design and a shorter warm-up time than the G6. In April 2025, Dexcom announced that the G7 15 Day had received FDA clearance for eligible adults aged 18 years and older with diabetes. Providing up to 15 days of sensor wear, the system was launched commercially in the U.S. on December 1, 2025, broadening Dexcom's product portfolio and its extended-wear CGM offering.

Dexcom G8 vs. G7: Revenue and Volume Outlook, 2027–2033

Dexcom unveiled the G8, its next-generation CGM, during its Investor Day in May 2026. The sensor is roughly 50% smaller than the G7 and is based on a new silicon chip, design, and algorithm. A self-adapting algorithm reads extra signals from the sensor to adapt to each user's body and cut down on outlier readings. Dexcom has established 15-day wear as the baseline for its sensors and says the G8 will cost less to manufacture than the G7. The company is aiming for an FDA submission in 2027, which would enable a launch in late 2027 or early 2028, along with a launch outside the U.S. planned for 2028. A multi-analyte version is planned to follow the first G8, with potassium, ketone, and lactate sensing in development and no timeline provided. During its Q2 2026 call in July, Dexcom maintained the G8 timeline and lifted its 2026 revenue guidance to USD 5.18–5.25 billion. Competitor Abbott secured FDA authorization for its dual glucose-ketone Libre Duo 10 Day in August 2026. Dexcom will report Q3 results in October 2026, the next opportunity for a G8 update.

G7 versus G8 at a glance

Dexcom Stelo: Revenue and Volume Outlook, 2024-2033

Dexcom's Stelo Glucose Biosensor, which launched in the U.S. in August 2024, represented the company's first step into the over-the-counter (OTC) glucose-monitoring market. Stelo was initially cleared for adults 18 years and older who do not use insulin, and it is intended for people with type 2 diabetes, prediabetes, and consumers looking for lifestyle-related glucose insights. Through a wearable sensor and a smartphone application, the system delivers continuous glucose readings without the need for a prescription.

In February 2026, Dexcom introduced enhanced AI-enabled food logging and personalized daily insights designed to help users see how nutrition and everyday behaviors influence their glucose patterns. A significant regulatory milestone came in June 2026, when the U.S. FDA cleared Stelo for children aged two years and older who do not use insulin, broadening its potential user base. Dexcom also revealed plans to expand internationally into the United Kingdom, Australia, New Zealand, and South Korea, starting later in 2026 and carrying on through 2027. These launches are planned and do not confirm that the product will be commercially available in every market.

The broadening of Stelo's indications, its digital features, and its potential geographic reach open up opportunities for growth in consumer glucose biosensing. Our report would estimate Stelo-specific revenue, sensor volumes, average selling prices, and regional expansion from 2024 to 2033, independent of Dexcom's prescription-based CGM systems.

Abbott Lingo: Revenue and Volume Outlook, 2024–2033

Abbott is extending its continuous glucose monitoring portfolio past conventional diabetes care with Lingo, an over the counter (OTC) glucose biosensor aimed at consumers who want to understand their glucose patterns and enhance their metabolic health. Lingo was introduced in the U.K. in early 2024 and became available in the U.S. in September 2024. The system pairs a wearable biosensor, usable for up to 14 days, with a smartphone app that delivers glucose trends, food and activity logging, personalized insights, and behavioral coaching.

A major step in Lingo’s expansion came with the addition of Android compatibility in December 2025, extending access to users beyond iOS. Abbott has further broadened the product’s retail availability, with purchases offered via its website and retailers such as Amazon and Walmart. In August 2026, Abbott and Google announced a partnership aimed at combining glucose insights with artificial intelligence to support everyday health and wellness, opening a potential opportunity to strengthen personalized consumer insights.

Lingo’s revenue outlook through 2033 will hinge on consumer awareness, how often sensors are replaced, subscription adoption, pricing, retail distribution, digital engagement, and entry into additional markets. The report will estimate Lingo-specific revenue, sensor volume, and average selling price separately from Abbott’s wider FreeStyle Libre portfolio and other diabetes-care products. Because Abbott does not publicly disclose standalone Lingo revenue and sensor sales, these figures will be derived through a documented estimation model rather than presented as reported company results.

Libre Duo and Libre Duo 10 Day: Revenue and Volume Outlook, 2026–2033

Abbott is expanding its continuous glucose monitoring portfolio through Libre Duo and Libre Duo 10 Day, wearable biosensors designed to measure glucose and ketone levels continuously. The systems represent an emerging development in diabetes monitoring, particularly for individuals at elevated risk of diabetic ketoacidosis (DKA). Abbott received CE marking in May 2026 for Libre Duo (adults, up to 15 days of wear) and Libre Duo 10 Day (ages 2 and older), and U.S. FDA authorization for Libre Duo 10 Day in August 2026, with commercial launches planned from late 2026. Sources: Abbott announcements and FDA information.

A key milestone in 2026 was the product's regulatory progress in Europe and the U.S., establishing a foundation for initial commercialization. The 10-day sensor wear period creates recurring replacement demand, while the combination of glucose and ketone monitoring may appeal to patients seeking greater visibility into their metabolic status.

Libre Duo's revenue outlook through 2033 will depend on market availability, eligible patient populations, sensor pricing, replacement frequency, reimbursement, physician recommendations, and adoption of continuous ketone monitoring. North America and Europe may represent important early markets, with Asia Pacific offering longer-term potential as access to advanced diabetes technologies expands.

The report will estimate Libre Duo-specific revenue, sensor volume, and average selling price separately from Abbott's broader FreeStyle Libre portfolio. As standalone product revenue and sales volumes are not publicly disclosed, these figures will be developed through a documented estimation model rather than presented as reported company results.

Market Opportunity 

The adoption potential for continuous dual glucose-ketone monitoring is expected to be varied across regions according to existing CGM penetration, diabetes technology infrastructure, reimbursement environments, regulatory availability and patient purchasing power.

North America is expected to represent an important early commercialization market owing to its established CGM ecosystem and high adoption of advanced diabetes technologies. Europe represents another significant opportunity with increasing CGM adoption and expanding availability of connected diabetes-management solutions.

Asia Pacific can represent a substantial longer-term opportunity owing to its large diabetes population, although adoption is expected to vary significantly between developed and emerging markets. Other regions may demonstrate comparatively gradual penetration as affordability and access remain important determinants of advanced monitoring adoption

Cross-brand Competitive Intelligence

We also support an extended universe of CGMs, primarily, Abbott FreeStyle Libre family and Libre Rio, MiniMed (spun out of Medtronic, March 2026), Senseonics Eversense 365, Roche Accu-Chek SmartGuide, i-SENS CareSens Air, Sinocare iCan.

The current status of CGM Products (October 2026) & Inclusion Criteria in the Product